Sona Nanotech Inc (SONA) AI Stock Analysis

• Market Cap: C$33.59M
• Dividend Yield: N/A
• Average Volume (3M): 26.50K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.63
• Revenue Growth: N/A
• EPS Growth: 5.23%
• Country: CA
• Employees: 8
• Sector: Healthcare
• Sector Strength: 46
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -0.03
• Shares Outstanding: 108,340,440
• 10 Day Avg. Volume: 23,438
• 30 Day Avg. Volume: 26,497
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• Price to Cash Flow (P/CF): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

Sona Nanotech's overall stock score reflects significant financial challenges with zero revenue and ongoing losses, which heavily weigh down its financial performance and valuation. However, the stock's neutral technical momentum and promising corporate developments in cancer therapy offer some optimism for future growth potential.

Sona Nanotech Inc Business Overview & Revenue Model

Company Description

Sona Nanotech Inc (SONA) is a nanotechnology company specializing in the development and commercialization of innovative nanomaterials for diagnostic and medical applications. The company operates primarily in the biotechnology and life sciences sectors, offering products such as gold nanorods for use in lateral flow assays and other diagnostic tests. Sona Nanotech is committed to advancing healthcare by providing high-performance, cost-effective solutions that enhance the accuracy and efficiency of diagnostic testing.

How the Company Makes Money

Sona Nanotech Inc generates revenue primarily through the sale of its proprietary nanomaterials, including gold nanorods, which are utilized in the production of diagnostic assays and other medical technologies. The company monetizes its technology by supplying these nanomaterials to diagnostic test manufacturers, research institutions, and healthcare companies. Additionally, Sona Nanotech may engage in licensing agreements and partnerships with other organizations to expand the application of its technologies and reach new markets. While direct sales of its nanomaterials form the core revenue stream, strategic collaborations and research grants may also contribute to the company's earnings.

Sona Nanotech Inc Financial Statement Overview

Summary

Sona Nanotech Inc. is facing severe financial challenges with zero revenue and consistent losses. Despite some improvement in stockholders' equity, the company struggles with high liabilities and negative cash flows, indicating ongoing financial instability.

Income Statement

Sona Nanotech Inc. has consistently reported zero revenue over multiple periods, indicating a significant challenge in generating sales. The company has experienced persistent negative gross profit and net income, leading to negative profit margins. The EBIT and EBITDA margins are also deeply negative, reflecting high operating losses.

Balance Sheet

Despite a challenging income statement, Sona Nanotech has managed to improve its stockholders' equity, turning positive in the most recent TTM period. However, the company still faces high liabilities and a concerning debt-to-equity ratio. The equity ratio is improving but remains low, suggesting potential financial instability.

Cash Flow

The company reports negative operating and free cash flow but has seen an increase in financing activities, indicating reliance on external funding. The free cash flow growth rate remains negative, reflecting ongoing cash flow challenges.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
0.00	0.00	0.00	0.00	0.00
	Gross Profit
-733.98K	-456.76K	-60.32K	-65.59K	-66.37K
	EBIT
-2.93M	-2.61M	-2.68M	-10.35M	-6.25M
	EBITDA
-2.00M	-2.02M	-2.34M	-10.38M	-6.24M
	Net Income Common Stockholders
-2.70M	-2.50M	-2.45M	-10.77M	-6.06M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
1.86M	115.38K	164.42K	1.20M	110.78K
	Total Assets
3.75M	2.75M	520.77K	1.52M	724.63K
	Total Debt
394.67K	527.68K	608.47K	1.34M	1.49M
	Net Debt
-1.46M	418.30K	453.05K	152.81K	1.39M
	Total Liabilities
1.24M	1.59M	1.03M	2.75M	4.16M
	Stockholders Equity
2.51M	1.16M	-507.86K	-1.22M	-3.44M
Cash Flow		Free Cash Flow
-1.96M	-1.26M	-1.81M	-3.81M	-4.75M
	Operating Cash Flow
-1.96M	-1.26M	-1.81M	-3.81M	-4.05M
	Investing Cash Flow
0.00	14.64K	0.00	0.00	-694.01K
	Financing Cash Flow
3.70M	1.20M	―	4.89M	4.27M

Sona Nanotech Inc Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.31
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:SONA, the sentiment is Positive. The current price of 0.31 is above the 20-day moving average (MA) of 0.29, above the 50-day MA of 0.29, and above the 200-day MA of 0.28, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 57.95 is Neutral, neither overbought nor oversold. The STOCH value of 66.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:SONA.

Sona Nanotech Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MBX	65 Neutral	C$55.00M	27.46	6.85%	―	2.72%	-47.79%
Sector *	52 Neutral	$5.15B	3.56	-42.52%	2.83%	14.56%	-0.53%
NANO	45 Neutral	C$78.01M	―	-84.80%	―	―	13.34%
SONA	40 Underperform	C$33.59M	―	-196.80%	―	―	5.23%

Sona Nanotech Inc Corporate Events

Sona Nanotech Advances Cancer Therapy with New Stock Option Grants

Sona Nanotech Inc. has announced the granting of 2,135,000 incentive stock options under its Stock Option Plan, with 1,855,000 options allocated to directors and officers. These options are part of the annual compensation for directors, aligning their interests with shareholders. The company is progressing towards a first-in-human clinical trial for its novel THT cancer treatment, with initial results expected this summer. This development is a significant step forward in Sona’s efforts to advance its innovative cancer therapy, potentially impacting its market position and stakeholder interests.

Spark’s Take on TSE:SONA Stock

According to Spark, TipRanks’ AI Analyst, TSE:SONA is a Underperform.

Sona Nanotech Inc. faces significant financial challenges with no revenue and negative cash flows, resulting in a very low financial performance score. While the technical analysis shows some neutral momentum, the negative P/E ratio and absence of dividends weigh on valuation. Positive corporate events offer some optimism, potentially positioning Sona as a future innovator in cancer treatments. However, these developments are still in early stages and not yet reflected in financial performance.

To see Spark’s full report on TSE:SONA stock, click here.

Sona Nanotech’s Cancer Therapy Shows Promising Preclinical Results

Sona Nanotech Inc. has released new preclinical data demonstrating the efficacy of its Targeted Hyperthermia Therapy (THT) in inhibiting tumor growth in an immunotherapy-resistant colorectal cancer model. The study showed that THT, when used in conjunction with a PD-1 inhibitor, resulted in a significant arrest of tumor growth in all test subjects. This promising result underscores the potential of THT to enhance the effectiveness of existing immunotherapies, positioning Sona as a significant player in cancer treatment innovation. The company is also engaging Proactive Investors North America Inc. to boost its global profile and public awareness.

Sona Nanotech to Present Innovative Cancer Therapy at Canadian Melanoma Conference

Sona Nanotech Inc. announced that its study on targeted intra-tumoral hyperthermia using biocompatible gold nanorods will be presented at the upcoming Canadian Melanoma Conference. This presentation highlights Sona’s innovative approach to cancer treatment, potentially impacting the industry by providing a safe, effective, and minimally invasive therapy option, which may serve as a valuable adjunct to existing treatments.